NDR's TVALA® Trademarked

The lead molecule under development by NDR for treating neuroinflammation is the retro-inverso thymopentin, TVALA®. The application for the novel drug is intended for use in ALS but it may be beneficial in renal dialysis patients as well as for Covid19 infections. TVALA® is the first molecule being developed by NDR. The potential ALS treatment was designed in a program to develop non-hydrolyzing analogs of anti-inflammatory peptides. TVALA® is scheduled for FDA review and into clinical trial less than 24 months after its conception in the laboratory. If successful, NDR may lead the way in shortening the pipeline of treatments to ALS patients by keeping the drug in the not-for-profit space.

25 views0 comments

Recent Posts

See All

San Francisco-based Verge Genomics has begun a phase 1 human trial for its ALS drug candidate, VRG50635, that was discovered by Artificial Intelligence, AI. This novel method of discovery may speed up

NDR is pleased to announce research support for Ghada Maged for an ALS biomarkers project. Ms. Maged is currently completing an M. Sc. degree in Master of Neuroscience at Alexandria University in Egyp